JSA
JSA has advised Rx Propellant in relation to its acquisition and investment of USD 200 million by Actis, a london-headquartered global investor.
Rx Propellant is a platform operating in the life sciences real estate sector focused in Hyderabad, Bengaluru and Mumbai regions.
Deal Value: USD 200 million.
JSA team comprised Partner – Rajeev Reddy and Senior Associate – Garima Sharma.
As per the rules of the Bar Council of India, we are not permitted to solicit work and advertise. By clicking on the “I AGREE” button below, you acknowledge the following:
If you have any legal issues, you, in all cases, must seek independent legal advice.
We use cookies to enhance your experience. By continuing to visit this website you agree to our use of cookies.
